Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-06
2010-10-05
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
07807641
ABSTRACT:
The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4839343 (1989-06-01), Waeber et al.
patent: 4891357 (1990-01-01), Kalra
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5423872 (1995-06-01), Cigaina et al.
patent: 5459039 (1995-10-01), Modrich et al.
patent: 5498531 (1996-03-01), Jarrell
patent: 5545549 (1996-08-01), Gerald et al.
patent: 5574010 (1996-11-01), McFadden
patent: 5604203 (1997-02-01), Balasubramaniam
patent: 5696093 (1997-12-01), Tseng et al.
patent: 5912227 (1999-06-01), Croom et al.
patent: 5916869 (1999-06-01), Croom, Jr. et al.
patent: 5939462 (1999-08-01), Connell et al.
patent: 5968819 (1999-10-01), Gerald et al.
patent: 5980945 (1999-11-01), Ruiz
patent: 5989920 (1999-11-01), Gerald et al.
patent: 6013622 (2000-01-01), Bruno et al.
patent: 6391343 (2002-05-01), Yen
patent: 6558708 (2003-05-01), Lin
patent: 6569832 (2003-05-01), Knudsen et al.
patent: 7396809 (2008-07-01), Lu et al.
patent: 2002/0094346 (2002-07-01), Lin
patent: 2003/0224983 (2003-12-01), Nielsen
patent: 2004/0228846 (2004-11-01), Pang et al.
patent: 2009/0082309 (2009-03-01), Bachovchin et al.
patent: 0 992 239 (2003-03-01), None
patent: WO-89/01967 (1989-03-01), None
patent: WO-90/02580 (1990-03-01), None
patent: WO-90/15637 (1990-12-01), None
patent: WO-91/10425 (1991-07-01), None
patent: WO-91/10470 (1991-07-01), None
patent: WO-9116917 (1991-11-01), None
patent: WO-94/16101 (1994-07-01), None
patent: WO-9517906 (1995-07-01), None
patent: WO-9616542 (1996-06-01), None
patent: WO-99/15516 (1999-04-01), None
patent: WO-00/47219 (2000-08-01), None
patent: WO-00/68197 (2000-11-01), None
patent: WO-01/62737 (2001-08-01), None
patent: WO-01/76631 (2001-10-01), None
patent: WO-03/026591 (2003-04-01), None
Marshall, A hierarchical approach to peptidomimetic design. Tetrahedron, vol. 49, Issue 17, pp. 3547-3558 (Mar. 23, 1993).
Ngo et al. The Protein Folding Problem and Tertiary Structure, pp. 433-440 and 492-495 (1994).
Adrian, T.E., et al., “Human Distribution and Release of a Putative New Gut Hormone, Peptide YY,” Gastroenterology, 89:1070-7 (1985).
Ahren et al., “Peptide YY Does not Inhibit Glucose-Stimulated Insulin Secretion in Humans,” European Journal of Endocrinology 134:362-365 (1996).
Allen, J.M., et al., “Effects of Peptide YY and Neuropeptide Y on Gastric Emptying in Man,” Digestion, 30:255-262 (1984).
Ando, R.; et al., “Feeding responses to several neuropeptide Y receptor agonists in the neonatal chick,” Eur J Pharmacol., 427(1):53-59 (2001).
Andres, C. J., et al., “Differentially functionalized diamines as novel ligands for the NPY2receptor,” Bioorg Med Chem Lett., 13(17):2883-2885 (2003).
Aponte et al., “Meal-Induced Peptide Tyrosine Tyrosine Inhibition of Pancreatic Secretion in the Rat,” The FASEB Journal 3:1949-1955 (1989).
Aponte, Gregory W., “PYY-mediated fatty acid induced intestinal differentiation”, Peptides 23, pp. 367-376 (2002).
Asakawa, A., et al., “Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice,” Peptides, 20:1445-1448 (1999).
Bader, R., et al., “Key Motif to Gain Selectivity at the Neuropeptide Y5-Receptor: Structure and Dynamics of Micelle-Bound [Ala31, Pro32]-NPY,” Biochemistry, 41(25):8031-8042 (2002).
Balasubramaniam, A., “Neuropeptide Y Family of Hormones: Receptor Subtypes and Antagonists,” Peptides, 18(3):445-457 (1997).
Balasubramaniam, A., et al., “Bis(31/31′){[Cys31, Nva34]NPY(27-36)-NH2}: a neuropeptide Y (NPY) Y5receptor selective agonist with a latent stimulatory effect on food intake in rats,” Peptides, 23(8):1485-1490 (2002).
Balasubramaniam, A., et al., “Structure-Activity Studies Including a (psi)(CH2-NH) Scan of Peptide YY (PYY) Active Site, PYY(22-36), for Interaction with Rat Intestinal PYY Receptors: Development of Analogues with Potent in Vivo Activity in the Intestine,” J. Med. Chem., 43:3420-3427 (2000).
Balasubramaniam, A., et al., “Structure-activity studies of peptide YY(22-36): N-α-Ac[Phe27]PYY(22-36), a potent antisecretory peptide in rat jejunum,” Peptides, 14(5):1011-1016 (1993).
Balasubramaniam, A., et al., “Syntheses and Receptor Affinities of Partial Sequences of Peptide YY (PYY),” Peptide Research, 1(1):32-35 (1988).
Balasubramaniam, A., et al., “Synthesis of neuropeptide Y,” Int J Pept Protein Res., 29(1):78-83 (1987).
Barany Francis, “Genetic Disease Detection and DNA Amplification Using Cloned Thermostable Ligase,” Proc. Natl. Acad. Sci. SA 88:189-193 (1991).
Batterham, R.L., et al., “Gut hormone PYY3-36 physiologically inhibits food intake,” Nature, 418:650-654 (2002).
Batterham, R.L., et al., “Inhibition of Food Intake in Obese Subjects by Peptide YY3-36,” N Engl J Med, 349(10):941-948 (2003).
Beck, A., et al., “Highly potent and small neuropeptide Y agonist obtained by linking NPY 1-4 via spacer to α-helical NPY 25-36,” FEBS Lett., 244(1):119-122 (1989).
Beck-Sickinger, A. G., et al., “Cyclopeptide analogs for characterization of the neuropeptide YY2-receptor,” J Recept Res., 13(1-4):215-228 (1993).
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 66(1):1-19 (1977).
Berglund, M. M., et al., “Recent Developments in Our Understanding of the Physiological Role of PP-Fold Peptide Receptor Subtypes,” Exp Biol Med (Maywood), 228(3):217-244 (2003).
Birdsall and Hulme, “Muscarinic Receptor Subclasses,” TIPS, pp: 459-463 (1983).
Bischoff, A. and Michel, M. C., “Emerging functions for neuropeptide Y5receptors,” Trends Pharmacol Sci., 20(3):104-106 (1999).
Bonaz, B., et al., “Peripheral peptide YY induces c-fos-like immunoreactivity in the rat brain,” Neuroscience Letters, 163:77-80 (1993).
Boublik, J. H., et al., “Synthesis and hypertensive activity of neuropeptide Y fragments and analogues with modified N- or C-termini or D-substitutions,” J Med Chem, 32(3):597-601 (1989).
Bousquet-Melou, et al., “Control of lipolysis in intra-abdominal fat cells of nonhuman primates: comparison with humans”, Journal of Lipid Research, 36, pp. 451-461 (1995).
Braesch et al., “Immune Response of Diabetic Patients against Transplanted Porcine Fetal Islet Cells., ”Transplantation Proceedings 24(2):679-680 (1992).
Brown, K.K., et al., “A Novel N-Aryl Tyrosine Activator of Peroxisome Proliferator-Activated Receptor-Y Reverses the Diabetic Phenotype of the Zucker Diabetic Fatty Rat,” Diabetes, 48:1415-1424 (1999).
Cabrele, C. and Beck-Sickinger, A. G., “Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family,” J Pept Sci., 6(3):97-122 (2000).
Cabrele, C., et al., “Ala31-Aib32: Identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor,” Biochemistry, 41(25):8043-8049 (2002).
Cabrele, C., et al., “The first selective agonist for the neuropeptide YY5receptor increases food intake in rats,” J Biol Chem., 275(46): 36043-36048 (2000).
Cabrele, C., et al., “Y-receptor affinity modulation by the design of pancreatic polypeptide
europeptide Y chimera led to Y5-receptor ligands with picomolar affinity,” Peptides, 22(3):365-378 (2001).
Campfield, L.A., et al., “Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks,” Science, 269(5223):546-549 (1995).
Chen, C., et al., “PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the D
Lu Kuanghui
Pang Kevin
Allen Marianne P
Curis, Inc.
DeBerry Regina M
Ropes & Gray LLP
LandOfFree
Methods and reagents for treating glucose metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for treating glucose metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for treating glucose metabolic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4228394